Topical treatment of common warts in an HIV-positive patient with imiquimod 5% cream

Clinical and Experimental Dermatology, Supplement

Volumn 28, Issue 1, 2003, Pages 48-50

  Juschka, U ^a   Hartmann, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EFAVIRENZ; HYDROXYDAUNORUBICIN; LAMIVUDINE PLUS ZIDOVUDINE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; ARTICLE; BURNING SENSATION; CASE REPORT; CELL DIVISION; ERYTHEMA; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION SENSITIVITY; MALE; PRIORITY JOURNAL; PRURITUS; RECURRENT INFECTION; RELAPSE; SIDE EFFECT; VERRUCA VULGARIS; WART VIRUS; AIDS RELATED COMPLEX; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; ANAMNESIS; BURN; CANCER SURGERY; CHEMOTHERAPY; COMORBIDITY; DISEASE ASSOCIATION; NONHODGKIN LYMPHOMA; RECURRENT DISEASE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMINOQUINOLINES; HUMANS; MALE; TREATMENT OUTCOME; WARTS;

EID: 1542644913     PISSN: 09663487     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.28.s1.16.x     Document Type: Article

References (11)

1. Severson J, Evans TY, Lee P et al. Human papillomavirus infections: epidemiology, pathogenesis and therapy. J Cut Med Surg 2001; 5: 43-60.
2. Phelps WC. Antiviral therapy for human papillomavirus rationale and prospects. Ann Int Med 1995; 123: 368-82.
3. Stender IM, Na R, Fogh H, Gluud C, Wulf HC. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000; 355: 963-6.
4. Hengge UR, Esser S, Schultewolter T et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143: 1026-31.
5. Strauss RM, Doyle EL, Mohsem AH, Green ST. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS 2001; 12: 264-6.
6. Kilkenny M, Merlin K, Young R, Marks R. The prevalence of common skin conditions in Australian school students: 1: common, plane and plantar viral warts. Br J Dermatol 1998; 138: 840-5.
7. Tschachler E, Bergstresser PR, Stingl G. HIV-related skin diseases. Lancet 1996; 348: 659-63.
8. Tyring SK, Arany I, Stanley MA et al. A randomised, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998; 178: 551-5.
9. Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134: 25-30.
10. Gilson RJ, Shupack JL, Friedman-Kien AE et al. A randomised, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS 1999; 13: 2397-404.
11. Saiag P, Bourgault-Villada I, Pavlovic M, Roudier-Pujol C. Efficacy of imiquimod on external anogenital warts in HIV-infected patients previously treated by highly active antiretroviral therapy. AIDS 2002; 16: 1438-40.